在130名患有巨巨乳血症的患者中,IgA型巨乳蛋白
Masayuki Ishihara1, Naoki Hattori1, Norito Nishiyama1,2
1Department of Orthopedic Surgery, Kansai Medical University, Osaka, Japan.
Clinical chemistry and laboratory medicine
|April 8, 2025
概括
存在IgA类型的宏蛋白质 (宏PRL),但IgG类型的宏PRL是最常见的. 这项研究阐明了不同宏观PRL类型在患者中的患病率和特征.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 临床化学 临床化学
背景情况:
- 巨乳蛋白 (宏-PRL) 是益乳蛋白 (PRL) 与免疫球蛋白G (IgG) 的复合物.
- 没有明确定义IgA型宏观PRL的存在和患病率.
研究的目的:
- 为了确定是否存在IgA型的宏观PRL.
- 与IgG类型相比,调查IgA类型宏观PRL的流行率.
- 分析宏观PRL类型之间的实验室数据差异.
主要方法:
- 通过使用聚乙烯糖醇沉和凝过色谱 (GFC) 分析了130名被诊断出患有巨型血的患者.
- 使用雅卡林列/SDS-PAGE和蛋白质G列识别的IgA型和IgG型宏PRL.
- 使用SDS-PAGE与IgA抗体和西部涂抹进行鉴定.
主要成果:
- 证实了IgA型宏PRL的存在.
- 患病率:83.8%为IgG型,7.7%为IgA型,5.4%为非IgA/非IgG型,以及3.1%为IgA加IgG型.
- 在IgA类型和IgG类型的宏观PRL之间,PRL或宏观PRL比率没有显著差异,但在非IgA/非IgG类型中比率较低.
结论:
- 已经证明存在IgA类型的巨乳蛋白.
- 最常见的形式是IgG类型的宏观PRL.
- 流行顺序:IgG型>IgA型>非IgA/非IgG型>IgA加IgG.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
120
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
120
Glucagon-like Receptor Agonists
272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
210
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
210
Myasthenia Gravis: Overview and Treatment
1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K


